AstraZeneca first to join FDA's push for patient-reported symptoms in cancer trials

The FDA and AstraZeneca are going beyond the label with cancer drugs—literally. In a new pilot program, the FDA will publish patient-reported symptoms that are collected during clinical trials but typically go undisclosed.